Main Line biopharm firm gets a boost from the FDA

The Food and Drug Administration has granted Orphan Drug Designation to an experimental therapy Marinus Pharmaceuticals is developing to treat Fragile X Syndrome. That prompts two questions: What is Fragile X Syndrome, and how is the Radnor, Pennsylvania, biopharmaceutical company’s new drug candidate attempting to treat the disorder. Fragile X syndrome is genetic condition that causes a range of developmental problems and symptoms, including cognitive i mpairment, learning disabilities and behavioral…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news